Table of Content

Chapter 1. Methodology & Sources

1.1. Market Definition
1.2. Research Scope
1.3. Methodology
1.4. Research Sources
1.4.1. Primary
1.4.2. Secondary
1.4.3. Paid Sources
1.5. Market Estimation Technique

Chapter 2. Executive Summary

2.1. Summary Snapshot, 2019-2027

Chapter 3. Key Insights

Chapter 4. In Silico Drug Artificial Intelligence Market Segmentation & Impact Analysis

4.1. In Silico Drug Artificial Intelligence Market Material Segmentation Analysis
4.2. Industrial Outlook
4.2.1. Market indicators analysis
4.2.2. Market drivers analysis
4.2.2.1. Emphasis on Reduction in Medical Errors and Readmission Rates
4.2.2.2. Growth in the Biomarker Identification Market
4.2.3. Market restraints analysis
4.2.3.1. Lack of High Complexity Testing Centers
4.3. Technological Insights
4.4. Regulatory Framework
4.5. Porter’s Five Forces Analysis
4.6. Competitive Metric Space Analysis
4.7. Price trend Analysis
4.8. Covid-19 Impact Analysis

Chapter 5. In Silico Drug Artificial Intelligence Market By Technology

5.1. Technology Dynamics & Market Share, 2023 & 2032
5.1.1. Artificial Intelligence
5.1.1.1. Target Identification
5.1.1.1.1. Reverse Docking
5.1.1.1.2. Bioinformatics
5.1.1.1.3. Protein Structure Prediction
5.1.1.2. Others

Chapter 6. In Silico Drug Artificial Intelligence Market By Product

6.1. Product Dynamics & Market Share, 2023 & 2032
6.1.1. Software
6.1.2. Software as a Service
6.1.3. Consultancy-as-a-Service

Chapter 7. In Silico Drug Artificial Intelligence Market By End User

7.1. End User of Large Molecule Dynamics & Market Share, 2023 & 2032
7.1.1. Pharmaceutical and Biopharmaceutical Companies
7.1.2. Contract Research Organizations
7.1.3. Academic and Research Institutes
7.1.4. Others

Chapter 8. In Silico Drug Artificial Intelligence Market By Workflow Insights & Trends Revenue (USD Billion)

8.1. End User Dynamics & Market Share, 2023 & 2032
8.1.1. Discovery
8.1.2. Pre-Clinical Tests
8.1.3. Clinical Tests
8.1.4. Others

Chapter 9. In Silico Drug Artificial Intelligence Market Regional Outlook

9.1. In Silico Drug Artificial Intelligence Market share By Region, 2023 & 2032
9.2. North America
9.2.1. Market By Workflow, Estimates and Forecast, USD Billion
9.2.1.1. Artificial Intelligence
9.2.1.1.1. Target Identification
9.2.1.1.1.1. Reverse Docking
9.2.1.1.1.2. Bioinformatics
9.2.1.1.1.3. Protein Structure Prediction
9.2.1.1.2. Others
9.2.1.1.3. Lead Artificial Intelligence
9.2.1.1.3.1. Pharmacophore
9.2.1.1.3.2. Library Design
9.2.1.2. Pre-Clinical Tests
9.2.1.3. Clinical Trials
9.2.2. Market By Product, Market Estimates and Forecast, USD Billion
9.2.2.1. Software
9.2.2.2. Software as a Service (Cloud)
9.2.2.3. Software
9.2.3. Market By End User of Large Molecule, Market Estimates and Forecast, USD Billion
9.2.3.1. Pharmaceutical and Biopharmaceutical Companies
9.2.3.2. Contract Research Organizations
9.2.3.3. Academic and Research Institutes
9.2.3.4. Others
9.2.4. Market By Workflow, Market Estimates and Forecast, USD Billion
9.2.4.1. Discovery
9.2.4.2. Pre-Clinical Tests
9.2.4.3. Clinical Tests
9.2.4.4. Others
9.2.5. Market By Country, Estimates and Forecast, USD Billion
9.2.5.1. US
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Market By Workflow, Estimates and Forecast, USD Billion
9.3.1.1. Artificial Intelligence
9.3.1.1.1. Target Identification
9.3.1.1.1.1. Reverse Docking
9.3.1.1.1.2. Bioinformatics
9.3.1.1.1.3. Protein Structure Prediction
9.3.1.1.2. Others
9.3.1.1.3. Lead Artificial Intelligence
9.3.1.1.3.1. Pharmacophore
9.3.1.1.3.2. Library Design
9.3.1.2. Pre-Clinical Tests
9.3.1.3. Clinical Trials
9.3.2. Market By Product, Market Estimates and Forecast, USD Billion
9.3.2.1. Software
9.3.2.2. Software as a Service (Cloud)
9.3.2.3. Software
9.3.3. Market By End User of Large Molecule, Market Estimates and Forecast, USD Billion
9.3.3.1. Pharmaceutical and Biopharmaceutical Companies
9.3.3.2. Contract Research Organizations
9.3.3.3. Academic and Research Institutes
9.3.3.4. Others
9.3.4. Market By Workflow , Market Estimates and Forecast, USD Billion
9.3.4.1. Discovery
9.3.4.2. Pre-Clinical Tests
9.3.4.3. Clinical Tests
9.3.4.4. Others
9.3.5. Market By Country, Estimates and Forecast, USD Billion
9.3.5.1. Germany
9.3.5.2. U.K.
9.3.5.3. France
9.3.5.4. BENELUX
9.3.5.5. Rest of Europe
9.4. Asia Pacific
9.4.1. Market By Workflow, Estimates and Forecast, USD Billion
9.4.1.1. Artificial Intelligence
9.4.1.1.1. Target Identification
9.4.1.1.1.1. Reverse Docking
9.4.1.1.1.2. Bioinformatics
9.4.1.1.1.3. Protein Structure Prediction
9.4.1.1.2. Others
9.4.1.1.3. Lead Artificial Intelligence
9.4.1.1.3.1. Pharmacophore
9.4.1.1.3.2. Library Design
9.4.1.2. Pre-Clinical Tests
9.4.1.3. Clinical Trials
9.4.2. Market By Product, Market Estimates and Forecast, USD Billion
9.4.2.1. Software
9.4.2.2. Software as a Service (Cloud)
9.4.2.3. Software
9.4.3. Market By End User of Large Molecule, Market Estimates and Forecast, USD Billion
9.4.3.1. Pharmaceutical and Biopharmaceutical Companies
9.4.3.2. Contract Research Organizations
9.4.3.3. Academic and Research Institutes
9.4.3.4. Others
9.4.3.5. Vectors
9.4.4. Market By Clinical Tests, Market Estimates and Forecast, USD Billion
9.4.4.1. Discovery
9.4.4.2. Pre-Clinical Tests
9.4.4.3. Clinical Tests
9.4.4.4. Others
9.4.5. Market By Country, Estimates and Forecast, USD Billion
9.4.5.1. China
9.4.5.2. Japan
9.4.5.3. South Korea
9.4.5.4. Rest of APAC
9.5. Latin America
9.5.1. Market By Workflow, Estimates and Forecast, USD Billion
9.5.1.1. Artificial Intelligence
9.5.1.1.1. Target Identification
9.5.1.1.1.1. Reverse Docking
9.5.1.1.1.2. Bioinformatics
9.5.1.1.1.3. Protein Structure Prediction
9.5.1.1.2. Others
9.5.1.1.3. Lead Artificial Intelligence
9.5.1.1.3.1. Pharmacophore
9.5.1.1.3.2. Library Design
9.5.1.2. Pre-Clinical Tests
9.5.1.3. Clinical Trials
9.5.2. Market By Product, Market Estimates and Forecast, USD Billion
9.5.2.1. Software
9.5.2.2. Software as a Service (Cloud)
9.5.2.3. Software
9.5.3. Market By End User of Large Molecule, Market Estimates and Forecast, USD Billion
9.5.3.1. Pharmaceutical and Biopharmaceutical Companies
9.5.3.2. Contract Research Organizations
9.5.3.3. Academic and Research Institutes
9.5.3.4. Others
9.5.3.5. Vectors
9.5.4. Market By Clinical Tests , Market Estimates and Forecast, USD Billion
9.5.4.1. Discovery
9.5.4.2. Discovery
9.5.4.3. Clinical Tests
9.5.4.4. Others
9.5.5. Market By Country, Estimates and Forecast, USD Billion
9.5.5.1. Brazil
9.5.5.2. Rest of LATAM
9.6. Middle East and Africa
9.6.1. Market By Workflow, Estimates and Forecast, USD Billion
9.6.1.1. Artificial Intelligence
9.6.1.1.1. Target Identification
9.6.1.1.1.1. Reverse Docking
9.6.1.1.1.2. Bioinformatics
9.6.1.1.1.3. Protein Structure Prediction
9.6.1.1.2. Others
9.6.1.1.3. Lead Artificial Intelligence
9.6.1.1.3.1. Pharmacophore
9.6.1.1.3.2. Library Design
9.6.1.2. Pre-Clinical Tests
9.6.1.3. Clinical Trials
9.6.2. Market By Product, Market Estimates and Forecast, USD Billion
9.6.2.1. Software
9.6.2.2. Software as a Service (Cloud)
9.6.2.3. Software
9.6.3. Market By End User of Large Molecule, Market Estimates and Forecast, USD Billion
9.6.3.1. Pharmaceutical and Biopharmaceutical Companies
9.6.3.2. Contract Research Organizations
9.6.3.3. Academic and Research Institutes
9.6.3.4. Others
9.6.3.5. Vectors
9.6.4. Market By Workflow, Market Estimates and Forecast, USD Billion
9.6.4.1. Discovery
9.6.4.2. Pre-Clinical Tests
9.6.4.3. Clinical Tests
9.6.4.4. Others
9.6.5. Market By Country, Estimates and Forecast, USD Billion
9.6.5.1. Saudi Arabia
9.6.5.2. UAE
9.6.5.3. Rest of MEA

Chapter 10. Competitive Landscape
10.1. Market Revenue Share By Manufacturers
10.2. Mergers & Acquisitions
10.3. Competitor’s Positioning
10.4. Strategy Benchmarking
10.5. Vendor Landscape
10.5.1. Raw Material Suppliers
10.5.1.1. North America
10.5.1.2. Europe
10.5.1.3. Asia Pacific
10.5.1.4. Middle East & Africa
10.5.1.5. Latin America
10.5.2. Distributors
10.5.2.1. North America
10.5.2.2. Europe
10.5.2.3. Asia Pacific
10.5.2.4. Middle East & Africa
10.5.2.5. Latin America
10.5.3. Others

Chapter 11. Company Profiles
11.1. Schrödinger Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Technology Insights
11.1.4. Strategic Initiatives
11.1.5. Emergen Research Insights
11.2. Dassault Systèmes .
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Technology Insights
11.2.4. Strategic Initiatives
11.2.5. Emergen Research Insights
11.3. OpenEye Scientific Software
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Technology Insights
11.3.4. Strategic Initiatives
11.3.5. Emergen Research Insights
11.4. Chemical Computing Group
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Technology Insights
11.4.4. Strategic Initiatives
11.4.5. Emergen Research Insights
11.5. Cresset Biomolecular Discovery Limited
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Technology Insights
11.5.4. Strategic Initiatives
11.5.5. Emergen Research Insights
11.6. Insilico Medicine
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Technology Insights
11.6.4. Strategic Initiatives
11.6.5. Emergen Research Insights
11.7. Atomwise Inc
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Technology Insights
11.7.4. Strategic Initiatives
11.7.5. Emergen Research Insights
11.8. Evotec
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Technology Insights
11.8.4. Strategic Initiatives
11.8.5. Emergen Research Insights
11.9. Charles River Laboratories
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Technology Insights
11.9.4. Strategic Initiatives
11.9.5. Emergen Research Insights
11.10. Ligand Pharmaceuticals Incorporated
11.10.1.Company Overview
11.10.2.Financial Performance
11.10.3.Technology Insights
11.10.4.Strategic Initiatives
11.10.5.Emergen Research Insights
11.11. Simulation Plus
11.11.1.Company Overview
11.11.2.Financial Performance
11.11.3.Technology Insights
11.11.4.Strategic Initiatives
11.11.5.Emergen Research Insights
11.12. Others
11.12.1.Company Overview
11.12.2.Financial Performance
11.12.3.Technology Insights
11.12.4.Strategic Initiatives
11.12.5.Emergen Research Insights